It aims to deliver excellence by creating a foundational, diverse, bio-asset that supports life science research, disease understanding, clinical trials and research and development, to deliver highest level of personalized, precise, and preventative healthcare for all.
Abu Dhabi Biobank will be a key pillar of health transformation, precision medicine, research, innovation, and socioeconomic growth by improving the well-being of people, not just patients, by bringing access to integrated, innovative, high-quality, and cost-effective healthcare.
The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, and M42, a global tech-enabled health powerhouse, have collaborated to launch a groundbreaking initiative and strategic priority, the Abu Dhabi Biobank, with its first offering being the region’s largest hybrid cord blood bank.
It will be a key pillar of health transformation and aims to deliver excellence by creating a diverse, foundational, bio-asset that supports therapeutic treatments, life science research for medical innovation, novel drug discovery targets and disease prevention, to deliver the highest level of personalized, precise, and preventative healthcare for all.
